KANSAS CITY, Kan. and BOSTON, July 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 862,500 additional shares of common stock, at a public offering price of $6.00 per share, in connection with its previously announced initial public offering of 5,750,000 shares of common stock that closed on July 2, 2013, bringing the total gross proceeds from the offering to $39,675,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics. The company's common stock is listed on The NASDAQ Global Market under the trading symbol "PETX." Stifel and Lazard Capital Markets acted as lead book-running managers for the offering. William Blair, JMP Securities and Craig-Hallum Capital Group acted as co-managers. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 26, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; or from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48 th Floor, New York, NY 10020, or by calling (800) 542-0970. Contacts:Tiberend Strategic Advisors, Inc.Joshua Drumm, Ph.D./ Andrew Mielachjdrumm@tiberend.com; (212) 375-2664 email@example.com; (212) 375-2694 SOURCE Aratana Therapeutics, Inc.